ASX ANNOUNCEMENT

ASX: CVB

8th July 2026

Appendix 4C & quarterly activity report – period ended 30 June 2026

Summary of key activities

- Purchase orders (POs) secured during Q4 FY26 totalled two (2) devices, both HiRise™ systems. Several advanced sales opportunities did not close before quarter-end and remain active. The Company expects these opportunities to contribute positively to purchase orders during Q1 FY27.

- CurveBeam AI generated customer receipts of A$2.58 million during the quarter, representing an 80% increase from A$1.43 million in the previous quarter.

- In Q4 FY26, the Company submitted responses to feedback from the National Medical Products Administration (NMPA) in China regarding its HiRise™ application. The Company continues to expect NMPA clearance during the second half of calendar year 2026. Regulatory clearance would trigger a A$1.0 million milestone payment from Weiying and is expected to be followed by Weiying/WEGO's initial order for U.S.-manufactured HiRise™ systems for distribution in China. Additional milestone payments of A$1.0 million and A$2.0 million are payable upon the sale of the first 10 and first 50 HiRise™ systems respectively, in addition to the revenue generated from product sales.

- Commercial launch preparations in China continued to advance during the quarter. Activities included Key Opinion outreach, identification of prospective reference sites, and training of personnel on HiRise™ manufacturing, assembly and service processes. The Company remains encouraged by the commitment to a successful market launch.

- The Company continued to work closely with the leading robotic surgery platform's R&D team during the quarter. As part of this process, the vendor evaluated five (5) HiRise™ datasets, comprising four (4) total knee arthroplasty cases and one (1) total hip arthroplasty case. All datasets met the vendor's image quality requirements, resulting in successful segmentation and landmark detection at par with supine (MDCT) data. The company is commencing collection of the final phase of patient data this week, in order to complete the validation file with the latest performance metrics. The Company remains committed to addressing any outstanding requirements identified through the validation process and will provide any additional support required to complete validation

- The Company is progressing collaboration with a second leading robotic surgery platform and has expanded its validation activities from total knee arthroplasty to include total hip arthroplasty, increasing the potential addressable market for HiRise™ within robotic-assisted orthopaedic surgery.

Melbourne, Australia & Hatfield, Pennsylvania: CurveBeam AI Limited (ASX: CVB, "**CurveBeam AI**" or the "**Company**"), a developer of point-of-care specialised medical imaging (CT) equipment and AI-enabled SaaS-based clinical assessment solutions, is pleased to announce its Appendix 4C and quarterly activity report for the period ended 30 June 2026 (**Q4 FY26**).

Telephone: +61 3 9620 0250
Email: info@curvebeamai.com
Website: curvebeamai.com

Corporate Office
Level 10, 10 Queen Street
Melbourne, Victoria, 3000, Australia

Global Operations Headquarters
2800 Bronze Dr., Suite 110
Hatfield, PA 19440 USA

Purchase Orders and Receipts
During Q4 FY26 CurveBeam AI received POs for two (2) HiRise™ devices. One device sale was in the US and the other to WEGO in China. Several advanced sales opportunities did not close before quarter-end and remain active. The Company expects these opportunities to contribute positively to purchase orders during Q1 FY27.



Receipts from customers for Q4 FY26 were A$2.58m, up 80% on Q3, and down 54% from the comparative quarter result in FY25 (A$5.61m).

The Company carried A$4.8m of purchase orders and receivables into Q4FY26, and carries A$4.2m into Q1 FY27. The revenue recognition cycle of the Company ranges typically from two-to-six months from PO to install and full payment.

China Strategy
CurveBeam AI continued to make meaningful progress executing its China commercialisation strategy during the quarter, with regulatory, commercial and market development activities advancing in parallel alongside strategic partner Weiying / WEGO Orthopaedics. Building on the strategic partnership, the Company remains focused on establishing HiRise™ as a leading weightbearing CT solution in the world's largest medical device market.

In Q4 FY26, the Company submitted responses to feedback from the National Medical Products Administration (NMPA) in China regarding its HiRise™ application. The Company continues to expect NMPA clearance during the second half of calendar year 2026. Regulatory clearance would trigger a A$1.0 million milestone payment from Weiying /WEGO and is expected to be followed by an initial order for U.S.-manufactured HiRise™ systems for distribution in China. Additional milestone payments of A$1.0 million and A$2.0 million are payable upon the sale of the first 10 and first 50 HiRise™ systems respectively, in addition to the revenue generated from product sales.

Commercial launch preparations in China continued to advance during the quarter. Activities included Key Opinion outreach, identification of prospective reference sites, and training of personnel on HiRise™ manufacturing, assembly and service processes. The Company remains encouraged by the commitment to a successful market launch. These activities are designed to support a successful market launch immediately following regulatory approval and reinforce the strong strategic alignment and commitment from both organisations to drive adoption of HiRise™

across China. This work builds on the broader technology transfer and market development program already underway and positions the partnership to accelerate sales following NMPA clearance.

Enhanced HiRise™ Validation
The Company continued to work closely with the R&D team for the leading robotic surgery platform during the quarter. As part of this process, the vendor processed five (5) HiRise™ datasets, comprising four (4) total knee arthroplasty cases and one (1) total hip arthroplasty case. All datasets met the vendor's image quality requirements, segmentation and landmarks for processing. During evaluation, three (3) of the four (4) knee datasets triggered the vendor's motion rod assessment algorithm. The Company believes these outcomes were attributable to imaging artefact associated with the metal rod rather than patient motion. Based on these findings, the Company has implemented software and hardware refinements designed to eliminate the artefact. The next phase of validation will focus on confirming performance using patient datasets collected across multiple clinical sites. The Company remains confident in the validation outcome and is committed to providing any additional support required to complete the process.

CurveBeam AI has now implemented significant product improvements, including enhanced patient stabilisation capabilities and software-based alignment refinements designed to meet the vendor's clinical and technical objectives. The Company is now in the final stages of validating these enhancements across two clinical sites, representing an important milestone towards completing the assessment process.

Multi-Detector CT (MDCT) Bone Mineral Density (BMD) FDA Clearance
CurveBeam continues to progress its Bone Mineral Density (BMD) software regulatory strategy, with the initial FDA clearance for the Company's MDCT BMD software module now targeted for Q2 FY27. Following constructive feedback from the FDA during the 510(k) review process, the Company is undertaking additional clinical data to further validate the automated region-of-interest selection functionality. The Company submitted its initial FDA 510(k) Class II application for the MDCT BMD module in Q2 FY26, representing an important milestone in establishing a scalable regulatory pathway for AI-enabled CT-based bone health assessment. The strategy remains to leverage this initial clearance as the foundation for a second regulatory submission to expand the BMD capability onto the HiRise™ platform. This planned Special 510(k) submission will be supported by targeted data collection currently being scoped and budgeted. The MDCT BMD module provides CurveBeam with an opportunity to address the significant unmet need for rapid fracture risk assessment in the elderly within acute care settings. The initial target market includes approximately 300,000 hip fracture patients annually across 2,000–2,400 acute care hospitals in the US, representing an estimated 135 patients per site per year. This inpatient application provides a complementary pathway to the broader HiRise™ point-of-care opportunity, where the integration of weight-bearing CT and BMD assessment has the potential to deliver comprehensive musculoskeletal evaluation in a single patient visit for total joint replacements.

Cashflows from Operations and Runway
Cashflows used in operations for Q4 FY26 was (A$2.429m) versus cash used in operations of (A$4.209m) in Q3 FY26, a reduction of 42%.

Receipts from customers for Q4 FY26 were A$2.58m, up from A$1.43m in Q3.

Appendix 4C Comparative Summary		FY2025				FY2026			
		Q1 Actual	Q2 Actual	Q3 Actual	Q4 Actual	Q1 Actual	Q2 Actual	Q3 Actual	Q4 Actual
1.1	**Receipts from Customers**	2,410	2,589	1,545	5,612	1,374	2,400	1,434	2,576
1.2	**Payments for:**								
a)	R&D	(376)	(257)	(304)	(232)	(323)	(256)	(153)	(275)
b)	Product manufacturing and operating costs	(2,582)	(1,990)	(1,409)	(565)	(641)	(1,783)	(1,554)	(1,011)
c)	Advertising & Marketing	(392)	(260)	(365)	(275)	(385)	(327)	(300)	(168)
d)	Leased Assets								
e)	Staff costs	(2,926)	(3,562)	(2,989)	(3,196)	(2,994)	(3,161)	(2,881)	(2,999)
f)	Admin & corporate costs	(939)	(1,069)	(891)	(953)	(1,374)	(1,483)	(793)	(774)
	Subtotal - Outflows	(7,215)	(7,138)	(5,958)	(5,221)	(5,717)	(7,010)	(5,681)	(5,227)
1.3	Dividends received								
1.4	Interest Received	58	68	46	15	9	30	26	13
1.5	Interest & other costs of finance paid		(86)		(4)		(132)		
1.6	Income Taxes Paid								
1.7	Government Grants & Tax Incentives		1,833			333	2,563	12	209
1.8	Other								
	Subtotal - Other	58	1,815	46	11	342	2,461	38	222
1.9	**Cash from (used in) Operations**	(4,747)	(2,734)	(4,367)	402	(4,001)	(2,149)	(4,209)	(2,429)
2.6	Cash flows from investing activities	(20)	-	-	(360)	-		-	-
3.1	Cash flows from financing activities	8,723	991	496	149	1,141	4,032	4,569	(208)
4.5	Exchange Movements	(272)	455	(15)	(107)	(16)	(23)	(75)	(38)
4.1	**Opening Cash**	6,448	10,132	8,844	4,958	5,042	2,166	4,026	4,311
	Net increase (decrease) in cash in the period	3,684	(1,288)	(3,886)	84	(2,876)	1,860	285	(2,675)
4.6	**Closing Cash**	10,132	8,844	4,958	5,042	2,166	4,026	4,311	1,636
	Quarters of Cash (Operating)	(2.13)	(3.23)	(1.14)	N/A	(0.54)	(1.87)	(1.02)	(0.67)

The quarter closed with a cash balance of A$1.64m, and the calculation in the Appendix 4C at item 8.5 of quarters of cash, based on the cash used in operating activities was 0.67.

The Company notes the following in respect of quarters of cash post the announced raising:

- The quarter closed with a cash balance of A$1.64m and A$4.16m of purchase orders and receivables carried into Q4.
- Post the announced A$5.0m placement, the proforma cash position will be $6.64m, excluding any funds from the SPP. On a proforma cash basis, this would be 2.7 quarters of cash.
- We remain positive with the outlook for Q1 FY27 and are prioritising installations and collection of receipts from customers.

Payments to related parties (Listing Rule 4.7C.3)

In accordance with Listing Rule 4.7C.3 and as outlined in Section 6.1 of the Appendix 4C, the Company made payments to related parties totalling A$230,000, comprising executive and non-executive directors' fees, salary, and superannuation.

Definitions

As previously noted, CurveBeam AI's key metrics are defined and interpreted as follows:

- Purchase order – a signed purchase order (PO) for a CT scanner (device). The Company considers POs to be a key metric as it reflects actual sales at any given time.
- Receipts from customers – any cash consideration received from a customer by CurveBeam AI, including initial deposits required at the time of an order being placed.
- Revenue – Revenue is recognised after the device (e.g., HiRise™) is delivered, installed and training has been completed. Depending on the customer site requirements, there

can be several months' delay from a signed purchase order to recognition of revenue. Thus, revenue may not be reflective of sales progress in each period.

The Company will report on POs and cash receipts in its Appendix 4C (quarterly) lodgements, while revenue will be reported in Appendix 4E (full year report) and Appendix 4D (half year report).

Release approved by the Board of Directors.

About CurveBeam AI Limited

CurveBeam AI (ASX:CVB) develops, manufactures and sells specialised medical imaging (CT) scanners, coupled with AI SaaS-based clinical assessment solutions, to support medical practitioners in the management of musculoskeletal conditions. The Company's flagship CT scanner, HiRise™, performs weight bearing CT scans as well as traditional non-weightbearing CT scans, providing a range of advantages over the use of traditional CT or MRI devices. CurveBeam AI has more than 70 employees with its corporate office, AI and IP functions located in Melbourne, VIC, Australia and global operations headquarters in Hatfield, Pennsylvania, USA.

For further information go to https://curvebeamai.com

About ShanDong WeiYing Intelligent Medical Technology Co., Ltd.

Shandong Weiying Intelligent Medical Technology Co., Ltd. is a newly established Chinese medical-technology company located in the Torch Hi-Tech Industrial Development Zone, Weihai, Shandong Province. The company is a joint venture between Shandong Weigao Haixing Medical Device Co., Ltd and other partners.

About Shandong Weigao Haixing Medical Device Co., Ltd

Shandong Weigao Haixing Medical Device Co., Ltd is a subsidiary of Shandong Weigao Orthopaedic Materials Co., Ltd. ("WEGO Orthopaedics"). WEGO Orthopaedics is a leading Chinese medical device company specialising in the research, development, manufacture, and sale of orthopaedic medical devices. Its core product portfolio includes orthopaedic implant systems and surgical instruments used in trauma, spine, joint replacement, and sports medicine procedures.

WEGO Orthopaedics is recognised as one of China's most comprehensive and competitive orthopaedic implant manufacturers, holding the largest domestic market share among orthopaedic device suppliers. The company has established a fully integrated R&D and manufacturing system, equipped with internationally advanced facilities and modern project management capabilities.

Through continuous innovation and product iteration, WEGO Orthopaedics has developed a broad and diversified product line that meets the full spectrum of clinical needs in orthopaedic surgery. The company is a subsidiary of the WEGO Group, one of China's largest and most diversified healthcare conglomerates.

Investor / media enquiries

Matthew Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
CURVEBEAM AI LIMITED (ASX : CVB)	
ABN	**Quarter ended ("current quarter")**
32 140 706 618	**30 June 2026**

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	2,576	7,784
1.2	Payments for		
	(a) research and development	(275)	(1,007)
	(b) product manufacturing and operating costs	(1,011)	(4,989)
	(c) advertising and marketing	(168)	(1,180)
	(d) leased assets	-	-
	(e) staff costs	(2,999)	(12,035)
	(f) administration and corporate costs	(774)	(4,424)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	13	78
1.5	Interest and other costs of finance paid	-	(132)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	209	3,117
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(2,429)**	**(12,788)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**0**	**0**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	10,500
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(75)	(685)
3.5	Proceeds from borrowings	-	2,295
3.6	Repayment of borrowings	-	(2,039)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (payments of lease liabilities)	(133)	(537)
3.10	**Net cash from / (used in) financing activities**	**(208)**	**9,534**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	4,311	5,042
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,429)	(12,788)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	0	0

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(208)	9,534
4.5	Effect of movement in exchange rates on cash held	(38)	(152)
4.6	**Cash and cash equivalents at end of period**	**1,636**	**1,636**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	1,636	4,311
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**1,636**	**4,311**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	230
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	**-**	**-**

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(2,429)
8.2	Cash and cash equivalents at quarter end (item 4.6)	1,636
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	1,636
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	0.67

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: As detailed in the accompanying quarterly activities report, net cash outflows are expected to decrease in the coming quarters as the company targets increases in collection from customers, and as the China NMPA clearance is achieved.

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: Yes. As detailed in the accompanying quarterly activities report, the Company has announced a capital raise, expected to raise at least $5m before costs of capital raise. Additionally, there are $6m of milestone payments from WEGO Orthopaedics, of which $1m is due from NMPA clearance of US manufactured HiRise, and $3m is due from HiRise sales targets.

8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?
Answer:	Yes, the entity expects to be able to continue its operations and to meet its business objectives, based on executing the key activities outlined in the accompanying quarterly activities report.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 8th July 2026

Authorised by: By order of the board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.